Table 2.
Characteristics and treatments of patients with COVID-19.
| Total patients (n = 166) | With CT evidence of fibrosis (group 1, n = 76) | Without CT evidence of fibrosis (group 2, n = 90) | P-value | |
|---|---|---|---|---|
| Age (years) | ||||
| Mean (Range) | 57 ± 15 (14–89) | 63 ± 11 (28–86) | 52 ± 16 (14–89) | <0.001 |
| Male sex | 69 (42%) | 37 (49%) | 32 (36%) | 0.087 |
| Time interval (median, days) | ||||
| From onset of symptom to peak CT | 20 (12–26) | 23 (16–28) | 18 (11–24) | 0.001 |
| From onset of symptom to follow-up CT | 56 (51–63) | 58 (54–66) | 54 (35–59) | <0.001 |
| Severity of illness | ||||
| Moderate | 39 (23%) | 10 (13%) | 29 (32%) | <0.001 |
| Severe | 113 (68%) | 54 (71%) | 59 (66%) | |
| Critical | 14 (8%) | 12 (16%) | 2 (2%) | |
| Treatments | ||||
| Oxygen support | 145/166 (87%) | 72/76 (95%) | 73/90 (81%) | 0.009 |
| Nasal cannula or face mask | 137/166 (83%) | 64/76 (84%) | 73/90 (81%) | 0.600 |
| Noninvasive mechanical ventilation | 7/166 (4%) | 7/76 (9%) | 0/90 (0%) | 0.011 |
| Invasive mechanical ventilation | 1/166 (1%) | 1/76 (1%) | 0/90 (0%) | 0.458 |
| Glucocorticoids (methylprednisolone) | 75/166 (45%) | 50/76 (66%) | 25/90 (28%) | <0.001 |
| Immunoglobulin | 57/166 (34%) | 35/76 (46%) | 22/90 (24%) | 0.003 |
| Antiviral agents | 159/166 (96%) | 75/76 (99%) | 84/90 (93%) | 0.186 |
| Antibiotics | 110/166 (66%) | 63/76 (83%) | 47/90 (52%) | <0.001 |
| Antifungal agents | 2/166 (1%) | 2/76 (3%) | 0/90 (0%) | 0.208 |
| ECMO | 0/166 (0%) | 0/76 (0%) | 0/90 (0%) | 1.000 |
| CRRT | 0/166 (0%) | 0/76 (0%) | 0/90 (0%) | 1.000 |
Data are n (%) or median (IQR). Mean age is mean ± standard deviation. COVID-19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenation; CRRT, continuous renal replacement therapy.